BRIEF published on 11/04/2024 at 11:51, 1 year 2 months ago Acticor Biotech: Publication of 2024 half-year financial results Biotechnology Finance Half-year Results Glenzocimab Judicial Recovery
PRESS RELEASE published on 11/04/2024 at 11:46, 1 year 2 months ago Inside Information / News release on accounts, results Acticor Biotech publishes its half-year financial results for 2024, highlighting repositioning of glenzocimab in STEMI treatment, receivership proceedings extension, and shareholder approvals Repositioning Shareholder Approvals ACTICOR BIOTECH Glenzocimab Half-year Financial Results
BRIEF published on 10/11/2024 at 17:50, 1 year 3 months ago Acticor Biotech Advances Glenzocimab in Myocardial Infarction Treatment Clinical Trials Myocardial Infarction ACTICOR BIOTECH Glenzocimab Cardiovascular Treatment
PRESS RELEASE published on 10/11/2024 at 17:45, 1 year 3 months ago Inside Information / Other news releases Acticor Biotech repositions glenzocimab in the treatment of myocardial infarction, evaluating efficacy and safety in phase 2 studies LIBERATE and GLORIA. Clinical trials aim to reduce infarct size and prevent complications Clinical Trials Phase 2b Myocardial Infarction ACTICOR BIOTECH Glenzocimab
BRIEF published on 07/09/2024 at 20:50, 1 year 6 months ago Acticor Biotech Reports 2023 Financial Results Financial Report Annual Results Capital Raising ACTICOR BIOTECH Glenzocimab
PRESS RELEASE published on 07/09/2024 at 20:45, 1 year 6 months ago Inside Information / News release on accounts, results Acticor Biotech publishes its 2023 annual results, financial highlights, and financing outlook. Annual General Meeting scheduled for September 13, 2024 Annual General Meeting Financial Highlights 2023 Annual Results ACTICOR BIOTECH Financing Outlook
BRIEF published on 05/15/2024 at 11:20, 1 year 7 months ago Results of the ACTISAVE study and future perspectives of ACTICOR BIOTECH Stroke Treatment ACTICOR BIOTECH Glenzocimab ESOC 2024 ACTISAVE Study
PRESS RELEASE published on 05/15/2024 at 11:15, 1 year 7 months ago Inside Information / Other news releases ACTICOR BIOTECH presents main results of phase 2/3 ACTISAVE study on stroke treatment at ESOC 2024, targeting specific subgroups for potential benefits Stroke Treatment ACTICOR BIOTECH ESOC 2024 ACTISAVE Study Patient Subgroups
Published on 01/10/2026 at 05:10, 1 day 18 hours ago Sekur Private Data Ltd. Announces Non-Brokered Private Placement
Published on 01/10/2026 at 00:45, 1 day 22 hours ago Digi Power X Announces Entry into Settlement Agreement
Published on 01/09/2026 at 23:30, 2 days ago Matador Technologies Announces Grant of Restricted Share Units to Management Team
Published on 01/09/2026 at 23:10, 2 days ago Usha Resources and Totec Resources Provide Supplemental Disclosure for Qualifying Transaction
Published on 01/11/2026 at 22:20, 1 hour 13 minutes ago Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Published on 01/10/2026 at 21:25, 1 day 2 hours ago CATL Opens Middle East's Largest New Energy Aftermarket Facility in Riyadh
Published on 01/10/2026 at 13:05, 1 day 10 hours ago SeaVerse Launches World's First AI Native Platform, "All in AI Native" Leads the Forward-Looking Revolution in AI Creation
Published on 01/09/2026 at 21:55, 2 days 1 hour ago Piramal Pharma Achieves Notable Score Increase on 2025 S&P Global Corporate Sustainability Assessment (CSA)
Published on 01/09/2026 at 18:36, 2 days 4 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 01/09/2026 at 18:30, 2 days 5 hours ago H2 2025 half yearly report on the liquidity agreement signed with the Gilbert Dupont brokerage firm
Published on 01/09/2026 at 17:45, 2 days 5 hours ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 01/09/2026 at 17:42, 2 days 5 hours ago Aéroports de Paris SA - Shares and voting rights as of 31 December 2025
Published on 01/08/2026 at 21:00, 3 days 2 hours ago Biannual report on SEB S.A.’S liquidity agreement
